Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03304054 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
A Phase 3 study, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT03304054 is a Phase 3 study that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 93 participants.
The verdict
NCT03304054, a Phase 3 study, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Amifampridine Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-04-18 |
| Est. Completion | 2020-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03304054
The ClinicalTrials.gov registry entry for NCT03304054 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03304054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03304054 about?
NCT03304054 is a clinical study titled "Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG". Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
What is the current status of trial NCT03304054?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2018-04-18. Estimated completion is 2020-03-15.
What interventions are being tested in trial NCT03304054?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Amifampridine Phosphate (DRUG).
Who is sponsoring clinical trial NCT03304054?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.